论文部分内容阅读
目的探讨匹多莫德辅助治疗新生儿感染性肺炎的临床疗效及对患儿免疫功能的影响。方法将新生儿感染性肺炎患儿206例随机分为研究组和对照组,每组103例,对照组采用常规疗法进行治疗,观察组采用常规疗法联合匹多莫德进行治疗,观察患儿治疗前后免疫学指标水平,比较2组患儿临床疗效。结果研究组患儿临床症状及体征、影像学异常情况消失时间及1年内患儿复发次数都显著低于对照组(P<0.05);研究组患儿CD3+CD4+、CD3+CD4+/CD3+CD8+指标水平均显著高于对照组(P<0.05),Ig E低于对照组(P<0.05)。结论匹多莫德辅助治疗新生儿感染性肺炎疗效显著,能显著提高患儿的免疫功能。
Objective To investigate the clinical efficacy of pidotimod in the treatment of neonatal pneumonia and its effect on immune function. Methods 206 cases of neonates with infectious pneumonia were randomly divided into study group and control group, with 103 cases in each group. The control group was treated by conventional therapy. The observation group was treated with conventional therapy combined with Pidotimod to observe the treatment of children Before and after the level of immunological indicators, the clinical efficacy of two groups were compared. Results The clinical symptoms and signs of the study group, the disappearance time of imaging abnormalities and the number of recurrent children in one year were significantly lower than those in the control group (P <0.05). The CD3 + CD4 +, CD3 + CD4 + / CD3 + CD8 + The index level was significantly higher than the control group (P <0.05), Ig E was lower than the control group (P <0.05). Conclusion Pidotimod adjuvant treatment of neonatal pneumonia is effective, can significantly improve children’s immune function.